Latest From PPD Inc.
ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.
When Josef von Rickenbach created Parexel, not only did he create a company, he also helped invent an industry. Now, 35 years later, the Swiss native has stepped aside from CEO to chairman, likening the experience to sending your child to college; painful but ultimately necessary.
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Pharmaceutical Product Development Inc.
- North America
- Parent & Subsidiaries
- PPD Inc.
- Senior Management
David Simmons, Chmn. & CEO
Robert Hureau, EVP, CFO
David Johnston, PhD, EVP, Global Clinical Dev.
William J Sharbaugh, COO
Anshul Thakral, Senior VP, Global Head of Biotech
Michael O Wilkinson, PhD, EVP & CIO
Paul Colvin, EVP, large biopharma partnerships
- Contact Info
Phone: (910) 251-0081
929 North Front St.
Wilmington, NC 28401-3331
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.